Harrow, Inc. Common Stock (HROW) Stock
Fundamentals
Source: third-party data provider, as of October 14, 2026
Compare with HROW
Recent news

Do Options Traders Know Something About Harrow Stock We Don't?
Do Options Traders Know Something About Harrow Stock We Don't?
HROW

Harrow Q2 Earnings Call Highlights
Harrow Q2 Earnings Call Highlights
HROW

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
HROW

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
HROW
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 20.88
- MACD 12/26/9
- -1.97
- EMA 9 of MACD
- -1.89
- MACD histogram
- -0.09
- SMA 50
- $35.88
- Price below SMA 50
- EMA 50
- $34.62
- Price below EMA 50
- SMA 200
- $39.75
- Price below SMA 200
- EMA 200
- $38.82
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Do Options Traders Know Something About Harrow Stock We Don't?
Do Options Traders Know Something About Harrow Stock We Don't?
HROW

Harrow Q2 Earnings Call Highlights
Harrow Q2 Earnings Call Highlights
HROW

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
HROW

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
HROW

HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
HROW

Harrow Q1 Earnings Call Highlights
Harrow Q1 Earnings Call Highlights
HROW

Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
HROW

Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
HROW

A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?
HROW

Harrow (HROW) Misses Q4 Earnings Estimates
Harrow (HROW) Misses Q4 Earnings Estimates
HROW
News tone: automated (AI) classification of the article's content, not a price prediction.
About Harrow, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark L. Baum J.D. | CEO, Chairman of the Board & Founder | 1972 |
| Mr. Francis W. Mullery | President & CEO of Harrow's ImprimisRx Division | — |
| Mr. Andrew R. Boll C.F.A., C.M.A. | President, CFO & Chief Accounting Officer | 1982 |
| Dr. Amir W. Shojaei Ph.D., Pharm.D. | Chief Scientific Officer | 1968 |
| Mr. Michael D. Biega | Vice President of Investor Relations & Communications | — |
| Mr. Brett A. Burrell | Vice President of Legal & Compliance | — |
| Ms. Kim Barratt | Chief Talent Officer | — |
| Dr. Mark A. Mannebach Ph.D., R.Ph. | Head of Regulatory Affairs & Pharmacovigilance | — |
| Dr. Prashanth S. Annavajjhala | Chief of Staff | — |
| Mr. Patrick W. Sullivan | Chief Commercial Officer | 1976 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 14, 2026
Technical indicators
- RSI 14
- 20.88
- MACD 12/26/9
- -1.97
- EMA 9 of MACD
- -1.89
- MACD histogram
- -0.09
- SMA 50
- $35.88
- Price below SMA 50
- EMA 50
- $34.62
- Price below EMA 50
- SMA 200
- $39.75
- Price below SMA 200
- EMA 200
- $38.82
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $45.00
- Average
- $54.00
- High
- $63.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +2.0 | -4.6 | -13.3 | |||||||||
| 2022 | -13.4 | -3.0 | -10.3 | -0.4 | +5.5 | +0.3 | -5.9 | +33.2 | +35.9 | -6.2 | -9.9 | +22.5 |
| 2023 | +1.6 | +18.1 | +15.3 | +20.3 | -27.1 | -2.4 | +20.3 | -28.2 | -7.2 | +3.2 | -31.4 | +20.3 |
| 2024 | -20.3 | +13.6 | +20.8 | -20.4 | +72.1 | +22.7 | +22.5 | +64.8 | +13.4 | +1.4 | -8.2 | -19.9 |
| 2025 | -16.0 | -5.9 | +3.8 | -0.8 | +12.4 | +1.9 | +3.2 | +24.9 | +27.7 | -21.9 | +16.2 | +23.2 |
| 2026 | -18.0 | +20.7 | -34.2 | +14.4 | -13.9 | +24.5 | -9.8 | -5.6 | -16.7 | -4.9 |



